China Life Sciences Investment Opportunities Attract Cross Border Tie Ups
This article was originally published in PharmAsia News
HONG KONG - As China ramps up to overtake Japan as the No. 2 pharmaceutical market in coming years, investors are entering the foray to get a foothold in the burgeoning China pharma market and some interesting partners are joining forces
You may also be interested in...
Despite increasing concerns over protectionist policies in China, Morgan Stanley believes that market-based choices will trump government policies during the next decade, leading to success for multinational companies over the long term in the world's fastest-growing market
HONG KONG - In the late 1980s, Warner-Lambert researcher Bruce Roth came up with atorvastatin and changed the pharmaceutical market, and social and healthcare awareness factors in the West that made Lipitor the biggest blockbuster ever are starting to show up in China and other Asian countries. Cholesterol, heart attacks and the gamut of cardiovascular diseases are on the rise as diets grow richer, lifestyles more sedentary and smoking remains prevalent
HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground